secwatch.observer — SEC 8-K summary
======================================

Issuer:     Maze Therapeutics, Inc. (MAZE)
CIK:        0001842295
Form:       8-K
Filed at:   2025-09-11T23:59:59+00:00
Accession:  0001193125-25-200760
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maze raises $150M at premium; Phase 1 MZE782 data positive, Phase 2 in 2026
---------------------------------------------------------------------------

- Oversubscribed private placement of $150M gross proceeds at $16.25/share (premium to last close), closed Sept 12.
- Issued 4M shares and 5.23M pre-funded warrants; investors include Frazier, Deep Track, Janus Henderson, others.
- Phase 1 MZE782 in 112 healthy volunteers: 42-fold urinary Phe excretion, no SAEs, well tolerated.
- Dose-dependent eGFR dip similar to SGLT2 inhibitors observed; plans for Phase 2 in PKU and CKD in 2026.
- Proceeds to advance MZE829 in APOL1 kidney disease, MZE782 Phase 2, Compass platform, and working capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842295/000119312525200760/0001193125-25-200760-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842295/000119312525200760/d90404d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-200760

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer